Fig. 4From: Comparative efficacy and safety of paricalcitol versus vitamin D receptor activators for dialysis patients with secondary hyperparathyroidism: a meta-analysis of randomized controlled trialsEffect of paricalcitol on end-of-treatment serum calcium and phosphorus as compared to other VDRAsBack to article page